Evidence map›Paper›PMID 30945006›Full record

ArticlePediatric nephrology (Berlin, Germany)2019

Kidney biopsy findings in children with sickle cell disease: a Midwest Pediatric Nephrology Consortium study.

Rima S Zahr, Marianne E Yee, Jack Weaver, Katherine Twombley, Raed Bou Matar, Diego Aviles, Rajasree Sreedharan, Michelle N Rheault, Rossana Malatesta-Muncher, Hillarey Stone and 9 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07175051 (Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07175051 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2026 to 2030Enrolled20ConditionsSickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaArmsEmpagliflozin (oral)
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Sickle Cell Disease and CKD: An Update.American journal of nephrology · 2024
    Review
  5. Glomerular hyperfiltration: part 2-clinical significance in children.Pediatric nephrology (Berlin, Germany) · 2023
    Review
  6. Sickle cell nephropathy: insights into the pediatric population.Pediatric nephrology (Berlin, Germany) · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Unmasking hypertension in children and adolescents with sickle/beta-thalassemia.Journal of clinical hypertension (Greenwich, Conn.) · 2020
    Article
  11. Blood pressure unknowns of sickle cell disease in children.Journal of clinical hypertension (Greenwich, Conn.) · 2020
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 1 country.

Rima S ZahrDepartment of Pediatrics, Division Nephrology and Hypertension, The University of Tennessee and Le Bonheur Children's Hospital, 49 N. Dunlap, Memphis, TN, 38105, USA. rzahr@uthsc.edu.ORCID 0000-0002-3631-7195
Marianne E YeeAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Division of Hematology/Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Jack WeaverLevine Children's Hospital, Charlotte, NC, USA.
Katherine TwombleyMedical University of South Carolina, Charleston, SC, USA.
Raed Bou MatarCleveland Clinic, Cleveland, OH, USA.
Diego AvilesDivision of Pediatric Nephrology, LSU Health Sciences Center and Children's Hospital New Orleans, New Orleans, LA, USA.
Rajasree SreedharanMedical College of Wisconsin, Milwaukee, WI, USA.
Michelle N RheaultUniversity of Minnesota, Minneapolis, MN, USA.
Rossana Malatesta-MuncherBaylor School of Medicine, Houston, TX, USA.
Hillarey StoneChildrens's Mercy Hospital, Kansas City, MO, USA.
Tarak SrivastavaChildrens's Mercy Hospital, Kansas City, MO, USA.
Gaurav KapurChildren's Hospital of Michigan, Wayne State University, Detroit, MI, USA.
Poornima BaddiChildren's Hospital of Michigan, Wayne State University, Detroit, MI, USA.
Oded VolovelskyCincinnati Children's Hospital, Cincinnati, OH, USA.
Jonathan PelletierDuke University, Durham, NC, USA.
Rasheed GbadegesinDuke University, Durham, NC, USA.
Wacharee SeeherunvongUniversity of Miami Miller School of Medicine, Miami, FL, USA.
Hiren P PatelNationwide Children's Hospital, Columbus, OH, USA.
Larry A GreenbaumDepartment of Pediatrics, Division of Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.
Duke University · USEmory University · USMercy Medical Center · USWayne State University · USBaylor School · USCincinnati Children's Hospital Medical Center · USCleveland Clinic · USLe Bonheur Children's Hospital · USLevine Children's Hospital · USLouisiana State University Health Sciences Center New Orleans · USMedical College of Wisconsin · USMedical University of South Carolina · USNationwide Children's Hospital · USUniversity of Miami · USUniversity of Minnesota · US

Funding

RESEARCH TRAINING IN PEDIATRIC NEPHROLOGYT32DK007695 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD · 1992 to 2023
$2.2M
6 · The paper itself

Abstract

backgroundRenal damage is a progressive complication of sickle cell disease (SCD). Microalbuminuria is common in children with SCD, while a smaller number of children have more severe renal manifestations necessitating kidney biopsy. There is limited information on renal biopsy findings in children with SCD and subsequent management and outcome.

methodsThis is a multicenter retrospective analysis of renal biopsy findings and clinical outcomes in children and adolescents with SCD. We included children and adolescents (age ≤ 20 years) with SCD who had a kidney biopsy performed at a pediatric nephrology unit. The clinical indication for biopsy, biopsy findings, subsequent treatments, and outcomes were analyzed.

resultsThirty-six SCD patients (ages 4-19 years) were identified from 14 centers with a median follow-up of 2.6 years (0.4-10.4 years). The indications for biopsy were proteinuria (92%) and elevated creatinine (30%). All biopsies had abnormal findings, including mesangial hypercellularity (75%), focal segmental glomerulosclerosis (30%), membranoproliferative glomerulonephritis (16%), and thrombotic microangiopathy (2%). There was increased use of hydroxyurea, angiotensin-converting-enzyme inhibitors, and angiotensin receptor blockers following renal biopsy. At last follow-up, 3 patients were deceased, 2 developed insulin-dependent diabetes mellitus, 6 initiated chronic hemodialysis, 1 received a bone marrow transplant, and 1 received a kidney transplant.

conclusionsRenal biopsies, while not commonly performed in children with SCD, were universally abnormal. Outcomes were poor in this cohort of patients despite a variety of post-biopsy interventions. Effective early intervention to prevent chronic kidney disease (CKD) is needed to reduce morbidity and mortality in children with SCD.

Indexed as

AdolescentAlbuminuriaAnemia, Sickle CellBiopsyChildChild, PreschoolDisease ProgressionFemaleFollow-Up StudiesGlomerular Filtration RateHumansKidneyMaleMidwestern United StatesRenal Insufficiency, ChronicRetrospective StudiesChildrenChronic kidney diseaseGlomerular hyperfiltrationGlomerulopathyProteinuriaSickle cell disease

Identifiers

PMID30945006
OpenAlexW2931598588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.